- Home
- EMCG vs IKNA Comparison
EMCG vs IKNA Comparison
Compare EMCG & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- IKNA
- Stock Information
- Founded
- EMCG 2021
- IKNA 2016
- Country
- EMCG United States
- IKNA United States
- Employees
- EMCG N/A
- IKNA N/A
- Industry
- EMCG
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- EMCG
- IKNA Health Care
- Exchange
- EMCG NYSE
- IKNA Nasdaq
- Market Cap
- EMCG 83.7M
- IKNA 83.0M
- IPO Year
- EMCG 2022
- IKNA 2021
- Fundamental
- Price
- EMCG $11.60
- IKNA $1.68
- Analyst Decision
- EMCG
- IKNA Buy
- Analyst Count
- EMCG 0
- IKNA 2
- Target Price
- EMCG N/A
- IKNA $3.00
- AVG Volume (30 Days)
- EMCG 3.2K
- IKNA 41.6K
- Earning Date
- EMCG 01-01-0001
- IKNA 11-07-2024
- Dividend Yield
- EMCG N/A
- IKNA N/A
- EPS Growth
- EMCG 186.72
- IKNA N/A
- EPS
- EMCG 0.24
- IKNA N/A
- Revenue
- EMCG N/A
- IKNA $1,844,000.00
- Revenue This Year
- EMCG N/A
- IKNA N/A
- Revenue Next Year
- EMCG N/A
- IKNA N/A
- P/E Ratio
- EMCG $48.18
- IKNA N/A
- Revenue Growth
- EMCG N/A
- IKNA N/A
- 52 Week Low
- EMCG $10.84
- IKNA $1.02
- 52 Week High
- EMCG $13.39
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- EMCG 73.32
- IKNA 51.57
- Support Level
- EMCG $11.47
- IKNA $1.68
- Resistance Level
- EMCG $11.62
- IKNA $1.78
- Average True Range (ATR)
- EMCG 0.01
- IKNA 0.04
- MACD
- EMCG 0.01
- IKNA 0.00
- Stochastic Oscillator
- EMCG 84.62
- IKNA 36.36
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.